Pathophysiological basis of low contrast visual acuity loss in multiple sclerosis

OBJECTIVE: There is currently an urgent need for reliable clinical biomarkers of remyelination to be used in Phase 2 and Phase 3 clinical trials. Low contrast visual acuity (LCVA) has been suggested as a functional measure of the integrity of the visual pathway. Therefore, the aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Triplett, James D., Yiannikas, Con, Barnett, Michael H., Parratt, John, Barton, Joshua, Graham, Stuart L., You, Yuyi, Klistorner, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292188/
https://www.ncbi.nlm.nih.gov/pubmed/30564617
http://dx.doi.org/10.1002/acn3.659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292188/
https://www.ncbi.nlm.nih.gov/pubmed/30564617
http://dx.doi.org/10.1002/acn3.659

Ejemplares similares